Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Prostate cancer: in favour of active surveillance--functional outcomes matter.

Pfister D.

Nat Rev Urol. 2013 May;10(5):263-5. doi: 10.1038/nrurol.2013.70. No abstract available.

PMID:
23567497
2.
3.

[What does "PSA recurrence mean? "Active surveillance" for all risk groups is an option].

Hautmann R.

Urologe A. 2006 Oct;45(10):1239. German. No abstract available.

PMID:
17006696
4.

The Mind: Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind?

Reis LO, Carter HB.

Int Braz J Urol. 2015 Jan-Feb;41(1):10-4. doi: 10.1590/S1677-5538.IBJU.2015.01.03. No abstract available.

5.

Prostate specific antigen screening and active surveillance in the elderly.

Konety BR.

J Urol. 2009 Apr;181(4):1534-5. doi: 10.1016/j.juro.2009.01.065. No abstract available.

PMID:
19230925
6.

Prostate cancer: active surveillance in African American men.

Moul JW.

Nat Rev Urol. 2013 Jun;10(6):311-2. doi: 10.1038/nrurol.2013.97. No abstract available.

PMID:
23649288
7.

Prostate cancer: reducing overtreatment: active surveillance in low-risk disease.

Whitson JM, Porten SP, Carroll PR.

Nat Rev Urol. 2011 Mar;8(3):124-5. doi: 10.1038/nrurol.2011.8. No abstract available.

PMID:
21304508
8.

Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

Eur Urol. 2015 Apr;67(4):619-26. doi: 10.1016/j.eururo.2014.10.010. Review.

9.

Prostate cancer: treatment triggers for patients on active surveillance.

Hilton WM, Parekh DJ.

Nat Rev Urol. 2011 Mar;8(3):126-7. doi: 10.1038/nrurol.2010.235. No abstract available.

PMID:
21243020
10.
11.

Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.

Shelton PQ, Ivanowicz AN, Wakeman CM, Rydberg MG, Norton J, Riggs SB, Teigland CM.

Urology. 2013 May;81(5):979-84. doi: 10.1016/j.urology.2012.10.089.

PMID:
23523297
12.

Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance.

Koo KC, Park SU, Rha KH, Hong SJ, Yang SC, Hong CH, Chung BH.

Jpn J Clin Oncol. 2015 Aug;45(8):785-90. doi: 10.1093/jjco/hyv073.

PMID:
25979243
13.

Population-Based Assessment of Determining Treatments for Prostate Cancer.

Chamie K, Williams SB, Hu JC.

JAMA Oncol. 2015 Apr;1(1):60-7. doi: 10.1001/jamaoncol.2014.192.

PMID:
26182305
14.

Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.

Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J.

Eur Urol. 2013 Jan;63(1):101-7. doi: 10.1016/j.eururo.2012.08.066.

PMID:
22980443
15.

Active surveillance as a treatment option for prostate cancer.

Hegarty J, Bailey DE Jr.

Semin Oncol Nurs. 2011 Nov;27(4):260-6. doi: 10.1016/j.soncn.2011.07.004.

PMID:
22018405
16.

[Prostate-specific antigen for treatment monitoring].

Graefen M, Fröhner M, Wirth M.

Urologe A. 2011 Mar;50(3):309-12. doi: 10.1007/s00120-010-2413-6. German.

PMID:
21365346
18.

PSA kinetics: no substitute for annual biopsy in prostate cancer surveillance?

Schmidt C.

J Natl Cancer Inst. 2010 Oct 20;102(20):1533-5. doi: 10.1093/jnci/djq424. No abstract available.

PMID:
20935269
19.

Active surveillance for prostate cancer: a review.

Klotz L.

Curr Urol Rep. 2010 May;11(3):165-71. doi: 10.1007/s11934-010-0110-z. Review.

PMID:
20425623
20.

Prostate cancer: modeling the outcomes of prostate cancer screening.

Loeb S, Carlsson S, Braithwaite RS.

Nat Rev Urol. 2012 Mar 13;9(4):183-5. doi: 10.1038/nrurol.2012.34. No abstract available.

PMID:
22410678

Supplemental Content

Support Center